A new generation of antipsychotics: pharmacology and clinical utility of cariprazine in schizophrenia
Open Access
- 1 August 2013
- journal article
- Published by Taylor & Francis in Therapeutics and Clinical Risk Management
- Vol. 9, 319-28
Abstract
Peer reviewed article authored by (Caccia S, Invernizzi RW, Nobili A, Pasina L). Read article or submit your manuscript for publishing.Keywords
This publication has 32 references indexed in Scilit:
- Discovery of cariprazine (RGH-188): A novel antipsychotic acting on dopamine D3/D2 receptorsBioorganic & Medicinal Chemistry Letters, 2012
- Comparative pharmacology of antipsychotics possessing combined dopamine D2 and serotonin 5-HT1A receptor propertiesPsychopharmacology, 2011
- Effects of aripiprazole, olanzapine, and haloperidol in a model of cognitive deficit of schizophrenia in rats: relationship with glutamate release in the medial prefrontal cortexPsychopharmacology, 2010
- Asenapine for schizophrenia and bipolar disorder: a review of the efficacy and safety profile for this newly approved sublingually absorbed second-generation antipsychoticInternational Journal Of Clinical Practice, 2009
- Atypical antipsychotic‐induced diabetes mellitus: an update on epidemiology and postulated mechanismsInternal Medicine Journal, 2008
- Pharmacogenetics and pharmacogenomics of schizophrenia: a review of last decade of researchMolecular Psychiatry, 2007
- Antipsychotic drugs and QTc prolongation: the potential role ofCYP2D6genetic polymorphismExpert Opinion on Drug Metabolism & Toxicology, 2007
- Metabolic considerations in the use of antipsychotic medications: a review of recent evidence.2007
- Lower Risk for Tardive Dyskinesia Associated With Second-Generation Antipsychotics: A Systematic Review of 1-Year StudiesAmerican Journal of Psychiatry, 2004
- Efficacy of newer generation antipsychotics in the treatment of schizophreniaPsychoneuroendocrinology, 2003